Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) have been given a consensus rating of “Hold” by the eleven ratings firms that are covering the firm, Marketbeat reports. Three analysts have rated the stock with a sell recommendation, one has issued a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $19.00.

FULC has been the topic of several research analyst reports. Bank of America boosted their price target on Fulcrum Therapeutics from $6.00 to $7.00 and gave the company an “underperform” rating in a research note on Tuesday, December 9th. Truist Financial lifted their price objective on shares of Fulcrum Therapeutics from $14.00 to $18.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Leerink Partners set a $20.00 price objective on Fulcrum Therapeutics and gave the company an “outperform” rating in a research report on Tuesday, October 21st. The Goldman Sachs Group restated a “positive” rating on shares of Fulcrum Therapeutics in a research report on Monday, December 8th. Finally, Piper Sandler reissued an “overweight” rating and issued a $23.00 price objective (up from $16.00) on shares of Fulcrum Therapeutics in a research note on Monday, December 8th.

Fulcrum Therapeutics Stock Up 1.7%

Shares of FULC opened at $12.00 on Thursday. The company has a 50 day moving average of $10.28 and a two-hundred day moving average of $8.41. Fulcrum Therapeutics has a twelve month low of $2.32 and a twelve month high of $15.74. The company has a market cap of $649.15 million, a price-to-earnings ratio of -10.17 and a beta of 3.17.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its quarterly earnings results on Wednesday, October 29th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.02). On average, sell-side analysts expect that Fulcrum Therapeutics will post -0.16 EPS for the current year.

Insider Buying and Selling

In other news, Director Robert J. Gould sold 15,000 shares of the stock in a transaction that occurred on Wednesday, November 19th. The shares were sold at an average price of $11.03, for a total value of $165,450.00. Following the completion of the sale, the director owned 484,864 shares of the company’s stock, valued at $5,348,049.92. This represents a 3.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of the stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $13.98, for a total value of $58,368,443.22. Following the completion of the transaction, the insider owned 6,053,960 shares of the company’s stock, valued at $84,634,360.80. The trade was a 40.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of FULC. Quarry LP purchased a new position in shares of Fulcrum Therapeutics during the 3rd quarter worth approximately $35,000. Farther Finance Advisors LLC increased its holdings in Fulcrum Therapeutics by 108.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 7,112 shares of the company’s stock worth $65,000 after purchasing an additional 3,697 shares during the period. Russell Investments Group Ltd. raised its holdings in Fulcrum Therapeutics by 4,209.3% in the second quarter. Russell Investments Group Ltd. now owns 9,308 shares of the company’s stock valued at $64,000 after acquiring an additional 9,092 shares in the last quarter. Assetmark Inc. acquired a new stake in shares of Fulcrum Therapeutics in the 3rd quarter valued at $88,000. Finally, Jump Financial LLC acquired a new position in shares of Fulcrum Therapeutics during the 1st quarter worth about $30,000. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.